Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 01 2022 - 3:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: April 1, 2022
Commission File Number: 001-39387
Renalytix plc
(Translation of registrant’s name into English)
Finsgate
5-7 Cranwood Street
London EC1V 9EE
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: ☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On March 31, 2022 Renalytix plc issued a press release announcing a $30.0 million financing package, which is furnished as Exhibit 99.1 to this Report on Form 6-K.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
RENALYTIX PLC |
|
|
By: |
|
/s/ James McCullough |
|
|
James McCullough |
|
|
Chief Executive Officer |
Date: April 1, 2022
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From May 2023 to May 2024